# Sorafenib to Treat FLT3-ITD AML

> **NCT02156297** · — · UNKNOWN · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 100 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- FLT3-ITD Mutation

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02156297
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-06
- **Primary completion:** 2020-05
- **Final completion:** 2022-08
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02156297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02156297, "Sorafenib to Treat FLT3-ITD AML". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02156297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*